Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States

Abstract

The US Food and Drug Administration approved a 6-month regimen of pretomanid, bedaquiline, and linezolid for extensively drug-resistant or multidrug-intolerant tuberculosis after a trial in South Africa demonstrated 90% effectiveness 6 months posttreatment. We report on a patient who completed the regimen using a lower linezolid dose.

Keywords

• tuberculosis and other mycobacteria
• antimicrobial resistance
• drug monitoring
• bedaquiline
• pretomanid
• linezolid